Inhibition Effect of TLR4mAb on mmLDL Impaired Endothelium-dependent Vasodilatation in Mouse Mesenteric Artery
CHEN Gen1,2, LIN Jie1, QIN Xu-ping2, ZHOU Nan3, LI Jie1,2*
1. The First People's Hospital of Chenzhou, Chenzhou 423000, China; 2. Institute of Drug and Pharmacology, University of South China, Hengyang 421001, China; 3. Medical College, Xi'an Jiaotong University, Xi'an 710061, China
Abstract��OBJECTIVE To investigate the effect and mechanism of TLR4 monoclonal antibody (TLR4mAb) on mmLDL induced impairment of endothelium-dependent vasodilatation in mouse mesenteric artery. METHODS The experiment established three groups of normal saline group, mmLDL treatment group and TLR4mAb intervention group. The concentration of IL-1�� and TNF-�� in plasma was determined by enzyme-linked immunosorbent assay (ELISA). Measurement of endothelium-dependent vasodilatation was achieved by microvascular tension mapping. Western blot and RT-PCR were used to investigate the expression level of protein and mRNA expressions in vascular tissues. In addition, ultra-structure of mesenteric artery endothelial cells was observed by transmission electron microscope. RESULTS TLR4mAb could improve the damage of mmLDL induced impairment of endothelium-dependent vasodilatation in a dose-dependent manner. Besides, TLR4mAb obviously up-regulated protein expressions in KCa3.1-channel and KCa2.3-channel, and down-regulated the expression of inflammatory factors TNF-�� and IL-1��. Furthermore, the improvement of mmLDL impaired vascular endothelial cells and endothelium-dependent vasodilatation might be correlated with its competitive antagonism of mmLDL-activated TLR4 signal transduction pathway and its downstream NF-��Bp65 and p-38 MAPK pathway. CONCLUSION Administration of TLR4mAb in advance can alleviate the impairment of endothelial cells and the decrease of endothelium-dependent vasodilatation induced by mmLDL, and inhibit the overexpression of inflammatory factors. Regulation of TLR4 pathway as well as its downstream NF-��Bp65 and P-38 MAPK pathways may be effective targets for the prevention and treatment of cardiovascular diseases.
BRIASOULIS A, TOUSOULIS D, ANDROULAKIS E S, et al. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Discov, 2012, 7(1): 21-32.
[2]
DONG Y, FERNANDES C, LIU Y, et al. Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis. Diabetes Vascul Dis Res, 2017, 14(1): 14.
[3]
MUDAU M, GENIS A, LOCHNER A, et al. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr, 2012, 23(4): 222-231.
[4]
YANG X, CHANG Y, WEI W. Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediat Inflamm, 2016, 2016(2): 1-9.
[5]
HONDA H M, LEITINGER N, FRANKEL M, et al. Induction of monocyte binding to endothelial cells by MM-LDL -Role of lipoxygenase metabolites. Arterioscl Thromb Vascul Biol, 1999, 19(3): 680-686.
[6]
LIAO F, BERLINER J A, MEHRABIAN M, et al. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest, 1991, 87(6): 2253-2257.
[7]
CHÁVEZ-SÁNCHEZ L, MADRID-MILLER A, CH��VEZ-RUEDA K, et al. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol, 2010, 71(8): 737-744.
[8]
HODGKINSON C P, LAXTON R C, PATEL K, et al. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol, 2008, 28(12): 2275-2281.
[9]
AKIRA S, TAKEDA K, KAISHO T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol, 2001, 2(8): 675-680.
[10]
PASTERKAMP G, VAN KEULEN J K, DE KLEIJN D P. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest, 2004, 34(5): 328-334.
[11]
BULUT Y, FAURE E, THOMAS L, et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol, 2002, 168(3): 1435-1440.
[12]
HENDERSON B, MARTIN A. Bacterial virulence in the moonlight: multitasking bacterial moonlighting proteins are virulence determinants in infectious disease. Infect Immun, 2011, 79(9): 3476-3491.
[13]
LIU Y, ZHANG Z, WANG L, et al. TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice. J Gastroenterol Hepatol, 2010, 25(1): 209-214.
[14]
YAO P, TAN F, GAO H, et al. Effects of probiotics on Toll-like receptor expression in ulcerative colitis rats induced by 2,4,6-trinitro-benzene sulfonic acid. Mol Med Reports, 2017, 15(4): 1973-1980.
[15]
CHEN G, WANG J J, XU C B, et al. Minimally modified LDL-induced impairment of endothelium-dependent relaxation in small mesenteric arteries of mice. J Vascul Res, 2013, 53(48): 58-71.
[16]
LIU Y, CHEN X L, XU C B, et al. Tail vein injection of mmLDL upregulates mouse mesenteric artery ETB receptors via activation of the ERK1/2 pathway. Vascul Pharmacol, 2017, 77: 80-88.
[17]
WANG J J, CHEN X L, XU C B, et al. The ERK1/2 pathway participates in the upregulation of the expression of mesenteric artery ��1 receptors by intravenous tail injections of mmLDL in mice. Vascul Pharmacol, 2015, 77: 33-39.
[18]
LI J, CAO Y X, LIU Y, et al. Minimally modified LDL upregulates endothelin type B receptors in rat basilar artery. Microvasc Res, 2012, 83(2): 178-184.
[19]
BARUCH A, VAN BRUGGEN N, KIM J B, et al. Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes. Curr Atheroscler Rep, 2013,15:327.
[20]
TRIPEPI G, MATTACE RASO F, SIJBRANDS E, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol, 2011, 6(7): 1714-1721.
[21]
MILLER Y I, VIRIYAKOSOL S, WORRALL D S, et al. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol, 2005, 25(6): 1213-1219.
[22]
TSIMIKAS S, MILLER Y I. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des, 2011, 17(1): 27-37.
[23]
HOLLESTELLE S C, DE VRIES M R, VAN KEULEN J K, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation, 2004, 109(3): 393-398.
[24]
BOEKHOLDT S M, AGEMA W R, PETERS R J, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation, 2003, 107(19): 2416-2421.
[25]
KIM F, PHAM M, LUTTRELL I, et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res, 2007, 100(11): 1589-1596.
[26]
REYNA S M, GHOSH S, TANTIWONG P, et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes, 2008, 57(10): 2595-2602.
[27]
SHI H, KOKOEVA M V, INOUYE K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest, 2006, 116(11): 3015-3025.
[28]
VITSEVA O I, TANRIVERDI K, TCHKONIA T T, et al. Inducible Toll-like receptor and NF-kappaB regulatory pathway expression in human adipose tissue. Obesity (Silver Spring), 2008, 16(5): 932-937.
[29]
ZHANG H M, CHEN L L, WANG L, et al. Macrophage infiltrates with high levels of Toll-like receptor 4 expression in white adipose tissues of male Chinese. Nutr Metab Cardiovasc Dis, 2009, 19(10): 736-743.
[30]
DASU M R, RAMIREZ S, ISSEROFF R R. Toll-like receptors and diabetes: a therapeutic perspective. Clin Sci (Lond), 2012, 122(5): 203-214.
[31]
KAWAI T, AKIRA S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 2010, 11(5): 373-384.
2019, Vol. 54 
